Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single Center Clinical Study to Examine the Safety and Efficacy of BCG Combined With Tislelizumab as Treatment for BCG-untreated Patients With High-grade Non-muscle-invasive Bladder Cancer

NCT05580354 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05580354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05580354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single Center Clinical Study to Examine the Safety and Efficacy of BCG Combined With Tislelizumab as Treatment for BCG-untreated Patients With High-grade Non-muscle-invasive Bladder Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
October 9, 2022
Completion date
May 31, 2025
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer